Pfizer Receives FDA Approval on Alopecia Areata Treatment Litfulo

Published on: 

Medication is the first of its kind approved for patients as young as 12.

Pfizer has officially announced that the FDA has approved Litfulo, an oral treatment for patients aged 12 and up with severe alopecia areata. According to the company, it is the first and only drug approved by the FDA for adolescents with the condition.


Pfizer describes Litfulo as a kinase inhibitor which inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases.

“LITFULO is an important treatment advancement for alopecia areata, an autoimmune disease that previously had no FDA-approved options for adolescents and limited options available for adults,” said Angela Hwang, chief commercial officer, president, global biopharmaceuticals business, Pfizer. “With today’s approval, adolescents and adults who struggle with substantial hair loss have an opportunity to achieve significant scalp hair regrowth.”

Reference: FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata. Pfizer. June 23, 2023. Accessed June 27, 2023.